SVRA
Savara, Inc.
$5.23
+1.36%
2026-05-08
About Savara, Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Key Fundamentals
Forward P/E
-15.77
EPS (TTM)
$-0.53
ROE
-63.4%
Profit Margin
0.0%
Debt/Equity
14.73
Price/Book
6.41
Beta
0.28
Market Cap
$1.05B
Avg Volume (10D)
1.1M
Recent Breakout Signals
No recent breakout signals detected for SVRA.
Recent Price Range (60 Days)
60D High
$6.24
60D Low
$4.81
Avg Volume
1.5M
Latest Close
$5.23
Get breakout alerts for SVRA
Sign up for Breakout Scanner to receive daily notifications when SVRA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Savara, Inc. (SVRA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SVRA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SVRA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.